83552-44-7 Usage
General Description
1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, (S)- is a chemical compound with a complex and unique structure. It is classified as a carboxylic acid and contains a spiro ring system, as well as sulfur and nitrogen atoms in its backbone. 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, (S)- is also chiral, with the (S)- enantiomer being the specific form specified in its name. Due to its intricate structure and chiral nature, it may have potential applications in pharmaceuticals, agrochemicals, or as a building block for other chemical synthesis. Additional research and testing would be necessary to fully understand its properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 83552-44-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,5,5 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 83552-44:
(7*8)+(6*3)+(5*5)+(4*5)+(3*2)+(2*4)+(1*4)=137
137 % 10 = 7
So 83552-44-7 is a valid CAS Registry Number.
83552-44-7Relevant articles and documents
Angiotensin Converting Enzyme Inhibitors: Spirapril and Related Compounds
Smith, Elizabeth M.,Swiss, Gerald F.,Neustadt, Bernard R.,McNamara, Paul,Gold, Elijah H.,et al.
, p. 1600 - 1606 (2007/10/02)
The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.
